期刊
CLINICAL CANCER RESEARCH
卷 22, 期 4, 页码 993-999出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-15-0943
关键词
-
类别
资金
- Breast Cancer Research Foundation (BCRF) [N003173]
- Avon Foundation [DODW81XWH-14-1-0284, NIH CA009071, CA168180, GM007309, CA167939]
- Sandy Garcia Charitable Foundation
- NIH [P30 CA006973]
- Commonwealth Foundation
- Santa Fe Foundation
- Breast Cancer Research Foundation
- Health Network Foundation
- ME Foundation
- Augustine Fellowship
- Walsh Fund
- Robin Page/Lebor Foundation
- Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale
Purpose: Mutations in the estrogen receptor (ER) a gene, ESR1, have been identified in breast cancer metastases after progression on endocrine therapies. Because of limitations of metastatic biopsies, the reported frequency of ESR1 mutations may be underestimated. Here, we show a high frequency of ESR1 mutations using circulating plasma tumor DNA (ptDNA) from patients with metastatic breast cancer. Experimental Design: We retrospectively obtained plasma samples from eight patients with known ESR1 mutations and three patients with wild-type ESR1 identified by next-generation sequencing (NGS) of biopsied metastatic tissues. Three common ESR1 mutations were queried for using droplet digital PCR (ddPCR). In a prospective cohort, metastatic tissue and plasma were collected contemporaneously from eight ER-pos-itive and four ER-negative patients. Tissue biopsies were sequenced by NGS, and ptDNA ESR1 mutations were analyzed by ddPCR. Results: In the retrospective cohort, all corresponding mutations were detected in ptDNA, with two patients harboring additional ESR1 mutations not present in their metastatic tissues. In the prospective cohort, three ER-positive patients did not have adequate tissue for NGS, and no ESR1 mutations were identified in tissue biopsies from the other nine patients. In contrast, ddPCR detected seven ptDNA ESR1 mutations in 6 of 12 patients (50%). Conclusions: We show that ESR1 mutations can occur at a high frequency and suggest that blood can be used to identify additional mutations not found by sequencing of a single metastatic lesion. (C) 2015 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据